Biocon’s arm inks pact with Endo to develop therapeutic molecules against cancer

21 Jul 2011 Evaluate

Syngene International, a subsidiary of Biocon, the Indian biotechnology major and Endo Pharmaceuticals have signed an agreement to expand their collaboration to develop novel biological therapeutic molecules against cancer. Syngene and Endo will partner on two new discovery programmes, strengthening their ongoing alliance in cancer research. Under the agreement, Endo will retain all the rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.

Thus, through the extended partnership, Syngene International and Endo Pharma will leverage their complementary and synergistic capabilities towards innovating novel therapeutic molecules for a robust cancer pipeline.

Syngene is India’s leading contract organization offering integrated drug and development service with capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, customs synthetics, process R&D and formulation development for small and large molecules.

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×